GeoVax Labs (NASDAQ:GOVX – Get Free Report) was upgraded by investment analysts at Roth Capital to a “strong-buy” rating in a report issued on Tuesday, Zacks.com reports.
GOVX has been the subject of several other reports. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a report on Tuesday, July 2nd. Roth Mkm began coverage on shares of GeoVax Labs in a research note on Tuesday. They set a “buy” rating and a $20.00 price objective for the company.
Check Out Our Latest Research Report on GeoVax Labs
GeoVax Labs Stock Performance
GeoVax Labs (NASDAQ:GOVX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($2.47) earnings per share for the quarter. As a group, equities analysts expect that GeoVax Labs will post -7.41 earnings per share for the current fiscal year.
Institutional Investors Weigh In On GeoVax Labs
A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC bought a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned 91.38% of GeoVax Labs as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 6.09% of the company’s stock.
GeoVax Labs Company Profile
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
Further Reading
- Five stocks we like better than GeoVax Labs
- 3 Tickers Leading a Meme Stock Revival
- Real Estate Stock Signals a Boom in Manufacturing Activity
- What Investors Need to Know to Beat the Market
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- Canada Bond Market Holiday: How to Invest and Trade
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.